bladder dysfunction
Conditions
Interventions
Control Group :Simple bladder function exercise
Western medicine treatment group:Bladder function exercise+Tamsulosin sustained-release capsules+Bromibestigmine tablets
Percutaneous acupoint electrical stimulation group:Bladder function exercise+percutaneous acupoint electrical stimulation
Combination therapy group:Bladder function exercise+medication treatment+percutaneous acupoint electrical stimulation
Sponsors
Obstetrics and Gynecology Hospital Affiliated to Fudan University
Eligibility
Sex/Gender
Female
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1) Patients aged 20-60 with cervical cancer stage Ib1-IIa2 (2009 FIGO cervical cancer clinical staging) undergoing radical hysterectomy; 2) Patients underwent surgical record confirmed radical hysterectomy; 3) Patients whose expected survival time of more than 12 months; 4) Patients who agree to participate in this experiment and have signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1) Patients who have received pelvic radiation therapy in the past; 2) Patients over 60 years old or under 20 years old; 3) Radical hysterectomy without surgical pathological confirmation; 4) Patients with previous symptoms such as urinary disorders, urinary incontinence, or abnormal preoperative urodynamic tests; 5) Patients with severe urinary tract infections or bladder vaginal fistula; 6) Concomitant urinary system tumors, urinary system stones, and other obstructive lesions of the urinary system; 7) In the acute phase of other diseases: consciousness disorders, body temperature above 38 ° C, unstable vital signs, or acute abdomen; 8) Patients with important organ dysfunction: liver enzymes>2 times the upper limit of normal, creatinine>2 times the upper limit of normal, blood amylase>2 times the upper limit of normal, heart function level 3-4, etc; 9) Brain disease, abnormal judgment ability; 10) Drug and/or alcohol abuse; 11) Mental illness patients receiving medication treatment; 12) I have participated in other clinical trials within 4 weeks prior to the start of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of urinary retention (residual urine measured after the first autonomic urination is greater than 100ml), reset catheterization; | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptoms related to patient urination;irritation sign of bladder;Autonomous recovery of urination time and urine volume;Incidence of urinary tract infections;Urinary retention and routine urine test within 2 weeks after catheter removal; | — |
Countries
China
Contacts
Public ContactYun Wang
Obstetrics and Gynecology Hospital Affiliated to Fudan University
Outcome results
None listed